Press releases
Year-end report July 1, 2023 – June 30, 2024
30 August, 2024Summary of year-end report Fourth quarter (2024-04-01 – 2024-06-30) Net sales amounted to SEK 0.0 million (0.0) Operating profit amounted to SEK -1.6 million (-1.3) Earnings per share* SEK -0.07 […]
DexTech Medical announces continued positive results from myeloma study
12 August, 2024The Phase 1 study examines the effect of OsteoDex on patients with progressive multiple myeloma (MM). Progressive disease means that the disease progresses and does not respond to existing treatment. […]
Interim report July 1, 2023 – March 31, 2024
26 April, 2024Summary of the third quarter (2024-01-01 – 2024-03-31) Net sales amounted to MSEK 0,0 (0,0) Operating profit/loss amounted to MSEK -1,5 (-1,6) Earnings per share* SEK -0.08 (-0.08) Summary of […]
DexTech Medical announces new positive results from the myeloma study
15 April, 2024The Phase 1 study investigates the efficacy of OsteoDex in patients with progressive multiple myeloma (MM). Progressive disease means that the disease progresses and does not respond to existing treatment. […]
Half-year report July 1 – December 31, 2023
15 February, 2024Summary of the second quarter (2023-10-01 – 2023-12-31) Net sales amounted to MSEK 0,0 (0,0) Operating profit/loss amounted to MSEK -1,4 (-1,2) Earnings per share* SEK -0,06 (-0.06) * Before […]
DexTech Medical announces positive results from the myeloma study
23 January, 2024The first test results from patient 1 have been received and show a very strong effect on the marker of osteoclast activity (CTX). The baseline value for CTX decreases by […]
DexTech Medical informs about the myeloma study, the first patient is treated
13 December, 2023The Phase 1 study investigates the efficacy of OsteoDex in patients with progressive multiple myeloma (MM). The first patient is treated during week 50 at Karolinska University Hospital in Huddinge. […]
Bulletin from the Annual General Meeting
31 October, 2023Today, October 31, 2023, the Annual General Meeting of DexTech Medical AB was held. All resolutions were passed with the required majority. Resolution on adoption of the income statement and […]
Interim report July 1- September 30, 2023
27 October, 2023Summary of the first quarter (2023-07-01 – 2023-09-30) Net sales amounted to MSEK 0,0 (0,0) Operating profit/loss amounted to MSEK -1,1 (-0,8) Earnings per share* SEK -0.05 (-0.04) Cash and […]
DexTech Medical files a new patent application with the European Patent Office
13 October, 2023Dextech has filed a new patent application regarding GMP production (Good Manufacturing Practice) of the company’s lead candidate OsteoDex with the European Patent Office (EPO.Org). The application describes a GMP […]